Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
wonder why they dont post these jobs on their website and linkedin....
you can spin this every way you want but this is hurting investors confidence and that is bad news and currently reflected in the SP. north of 100P will be a very long play for Argo unfortunately. Nice ramping game as with many AIM stocks
This therapy is already on the market for some time in 2017 Astra Zeneca stopped with SNG001 is the 220 person Astma trial due to lack of data (very low number of reported severe exacerbations) . Synairgen's own phase 2 trail with astma patients missed primary endpoint of change in asthma symptoms, RM thought that SNG001 could be helpfull now for COPD patinet with regular cold and virusses. The recent RNS shows some limited possitve results.
Very happy to see the positive results of the P2 trial for Covid and the start of P3 but this good go sideways and COPD is not convincing yet so Synairgen is beat er bust share....any thoughts?
hopefully we can see sooner than expected results..summer is far away and there will be less focus on covid and vaccines might have effect as well. Seen an article of patient in P2 trial who recovered after 2 days with SNG001 cant find it anymore but that could be really hulpfull if they see such an improvement they will stop trial and go on to threatment of larger groups
having similar issues buying , bit surprised to see that people on this group bought below 100...even last week it was impossible to buy the lows ...a bit annoyed on my top up at 120 last week ..now i will wait let's see how it wokrs out btc is stable right now
Argo will increase their number of machines significantly and the btc price is rising steadily. what is roughly the impact of the increase of the btc and the compute needed to mine a new bitcoin at a higher price?
Although ODX has some unique products they are not the go to market party that will hurt their margins since the manufactering party is not the place where the money will end up and there will be a constant price pressure on ODX since the go to market partys will be evaluating alternatives to be part of their products. So the sales numbers have to be huge to make any significant profit.
it will be a close call even if p3 data is showing positive results. The number of (old) medication that seems to work in covid patients is increasing by the day. Another study in dutch hospitals shows more than promosing results of rheumatism medication on patients. SNG stock is being threated as a covid stock so it will be miss or hit with significant upside but significant downside risk. RM is not interested in SP since SP of SNG has been below 20p for years so if is goes back to 20p he wont really care. They will annouce when there is news (bad or good) but the clock is ticking ..good luck
since there are several trials it could be difficult to enroll patients into trials which could delay ours as well. And if there are big names in need of patients for trials they will use their network to ensure a fast enrollment of trial patients, for example this one (https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-start-of-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/) they are lookimng for 300 patients and next phase an additional 700. This could influence our trial enrollment which is going slower than we all expected.
that sums it all up @teabiscuit a lot of people want a multi bagger and are getting impatient/worried and the longer it takes before a real RNS on sales there unfortunately is a lot to worry about ..
SP will be stuck between 60-70 until we get a real update on numbers like revenue, profit, contracts outlook. This approval will be a non event just like the CE mark all good to have but at the end irrilevant. Wish you all a happy new year !